Ruxolitinib decreased hematocrit, spleen volume in hydroxyurea-resistant polycythemia vera

  • June 17, 2014

CHICAGO — Ruxolitinib achieved superior disease control compared with best available therapy in patients with polycythemia vera who were resistant to or intolerant of hydroxyurea, according to results of the phase 3 RESPONSE trial presented at the ASCO Annual Meeting.

Ruxolitinib (Jakafi, Incyte), a JAK1 and JAK2 inhibitor, significantly improved hematocrit control without the need for phlebotomy, results showed. It also was more effective with regard to reduction of spleen volume, normalization of blood cell count and decrease in polycythemia vera-related systemic symptoms.

More »

Additional headlines from 2014 ASCO Annual Meeting

See All »